DWP16001 is one of 148 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
242 competitors in Efficacy and Safety
Gilotrif
Tegoprazan
DWP16001
Romiplostim N01
S1,
Imlifidase
INZ-701
Rhtpo
IN-B00009
KSI-101
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details